Sameer Zar - The Royal Marsden

More documents

Recommendations

Info

The Royal Marsden Screening and Surveillance in Barrett’s Oesophagus Medical Society Recommendations for Screening and Surveillance Endorsement: BSG, ACG, ASGE No endorsement: AGA No Quality Trial Data of Natural History and Screening/Surveillance Observational data Computer simulation models
23 The Royal Marsden Change Presentation title and date in Footer dd.mm.yyyy Screening and Surveillance for Oesophageal Adenocarcinoma How many patients with early oesophageal adenocarcinoma can be potentially indentified through screening and surveillance? 1 90-100% 2 75% 3 50% 4 20-25% 5 10%
Page 1 and 2: The Royal Marsden Barrett’s Oesop
Page 3 and 4: 3 The Royal Marsden Diagnosis of Ba
Page 5 and 6: 5 The Royal Marsden Clinical Featur
Page 7 and 8: 7 The Royal Marsden Risk Factors As
Page 9 and 10: 9 The Royal Marsden Change Presenta
Page 11 and 12: The Royal Marsden Change Presentati
Page 17 and 18: 17 The Royal Marsden Surveillance o
Page 19 and 20: 19 The Royal Marsden Risk Factors A
Page 21: 21 The Royal Marsden Screening For
Page 25 and 26: 25 The Royal Marsden Screening and
Page 27 and 28: How to Improve Screening for Barret
Page 29 and 30: 29 The Royal Marsden Change Present
Page 31 and 32: 31 The Royal Marsden Managing Cance
Page 35 and 36: 35 The Royal Marsden Cancer Risk in
Page 37 and 38: 37 The Royal Marsden Management of
Page 39 and 40: 39 The Royal Marsden Twice Daily do
Page 41 and 42: 41 The Royal Marsden Management of
Page 43 and 44: 43 The Royal Marsden Management opt
Page 49 and 50: 49 The Royal Marsden Endoscopic Muc
Page 53 and 54: 53 The Royal Marsden ESD for Barret
Page 55 and 56: 55 The Royal Marsden Endotherapy in
Page 57 and 58: The Royal Marsden Primary Preventio
Page 59: The Royal Marsden Conclusion - Scre

Sameer Zar - The Royal Marsden

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?